Published in J Natl Cancer Inst on March 16, 2005
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer (2008) 4.64
Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol (2012) 2.62
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
High prevalence of screen detected prostate cancer in West Africans: implications for racial disparity of prostate cancer. J Urol (2014) 2.17
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. J Urol (2009) 1.55
Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics (2010) 1.42
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol (2011) 1.36
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Prostate-specific antigen in the early detection of prostate cancer. CMAJ (2007) 1.13
Cancer screening in renal transplant recipients: what is the evidence? Clin J Am Soc Nephrol (2008) 1.06
Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol (2008) 1.05
Best practice in primary care pathology: review 4. J Clin Pathol (2006) 1.00
Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl (2012) 0.95
Should Canadians be offered systematic prostate cancer screening? No. Can Fam Physician (2007) 0.95
Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int (2008) 0.92
Prostate-specific antigen screening: pro. Curr Opin Urol (2010) 0.88
Population-based case-control study of PSA and DRE screening on prostate cancer mortality. Urology (2007) 0.82
Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml. Chin Med J (Engl) (2016) 0.80
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2015) 0.79
Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J Androl (2015) 0.79
Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening. J Cancer Res Clin Oncol (2013) 0.79
ProCOC: the prostate cancer outcomes cohort study. BMC Urol (2008) 0.78
Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans? Urol Oncol (2013) 0.78
Prostate cancer antigen 3 and genetic risk score as markers for the detection of prostate cancer in the Chinese population. Asian J Androl (2015) 0.77
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis. Ont Health Technol Assess Ser (2015) 0.77
Association between family history of prostate cancer and positive biopsies in a Brazilian screening program. World J Urol (2012) 0.76
Lack of follow-up of prostate-specific antigen test results. Public Health Rep (2009) 0.76
Correlation between CT perfusion and clinico-pathological features in prostate cancer: a prospective study. Med Sci Monit (2015) 0.76
Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts. World J Urol (2011) 0.76
Algorithms, nomograms and the detection of indolent prostate cancer. World J Urol (2008) 0.75
Trichomonas vaginalis infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO Trial. Cancer Causes Control (2017) 0.75
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
Long-term mortality after screening for colorectal cancer. N Engl J Med (2013) 5.81
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol (2004) 5.38
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med (2014) 4.76
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol (2004) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA (2011) 4.46
Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31
Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke (2003) 4.13
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA (2003) 3.82
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51